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ABSTRACT
Objective To compare rapid diagnostic tests (RDTs) for
malaria with routine microscopy in guiding treatment
decisions for febrile patients.
Design Randomised trial.
Setting Outpatient departments in northeast Tanzania at
varying levels of malaria transmission.
Participants 2416 patients for whom a malaria test was
requested.
Intervention Staff received training on rapid diagnostic
tests; patients sent for malaria tests were randomised to
rapid diagnostic test or routine microscopy
Main outcome measure Proportion of patients with a
negative test prescribed an antimalarial drug.
Results Of 7589 outpatient consultations, 2425 (32%)
had a malaria test requested. Of 1204 patients
randomised to microscopy, 1030 (86%) tested negative
for malaria; 523 (51%) of these were treated with an
antimalarial drug. Of 1193 patients randomised to rapid
diagnostic test, 1005 (84%) tested negative; 540 (54%)
of these were treated for malaria (odds ratio 1.13, 95%
confidence interval 0.95 to 1.34; P=0.18). Children aged
under 5 with negative rapid diagnostic tests were more
likely to be prescribed an antimalarial drug than were
those with negative slides (P=0.003). Patients with a
negative test by any method were more likely to be
prescribed an antibiotic (odds ratio 6.42, 4.72 to 8.75;
P<0.001). More than 90% of prescriptions for antimalarial
drugs in low-moderate transmission settings were for
patients for whom a test requested by a clinician was
negative for malaria.
Conclusions Although many cases of malaria are missed
outside the formal sector, within it malaria is massively
over-diagnosed. This threatens the sustainability of
deployment of artemisinin combination treatment, and
treatable bacterial diseases are likely to bemissed. Use of
rapid diagnostic tests, with basic training for clinical staff,
did not in itself lead to any reduction in over-treatment for
malaria. Interventions to improve clinicians’management
of febrile illness are essential but will not be easy.
Trial registration Clinical trials NCT00146796.
INTRODUCTION
Malaria is the most common single diagnosis made in
most countries in Africa,1 but the accuracy of clinical
diagnosis is limited by the low specificity of symptoms
and signs of malaria.2-4 Presumptive antimalarial treat-
ment for any fever with no obvious alternative cause is
widely practised, and studies suggest that this leads to
significant overuse of antimalarial drugs throughout
Africa.5-9 This over-diagnosis of malaria in the formal
healthcare sector coexists with under-diagnosis of
malaria in the community, with the result that anti-
malarials are given to people who do not need them
and not given to children who do.
With the growth of resistance to older antimalarial
drugs, newer but more expensive drugs need to be
used, and artemisinin combination treatment is now
being introduced in most African countries.10 11 The
cost of these drugs – up to 10 times that of current
antimalarial drugs – is their major constraint, and
deployment to people who need them is likely to
depend on subsidy.12 This may become unsustainable
if most antimalarial drugs continue to be given to
patients who do not have malaria. If patients with bac-
terial disease, an important cause of avoidable death in
children in Africa,13 14 are treated as malaria cases they
may not receive appropriate treatment.8 Improving
the diagnosis of acute febrile illness so that antimalarial
drugs are targeted to patients who need them and alter-
native diagnoses sought in others is therefore a public
health priority in Africa.
Rapid diagnostic tests have considerable potential as
a tool to improve the diagnosis of malaria.15 16 Several
commercially available tests are sensitive, specific, and
stable under operational conditions.17 Although
microscopy remains the gold standard for diagnosis
of malaria, its accuracy under operational conditions
in Africa is often low, and clinicians are aware of
this.4 Results of rapid diagnostic tests are rapidly avail-
able, less liable to the theoretical risk of being falsely
negative due to parasite sequestration, and visible to
both prescriber and patient, and they may result in
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greater respect for test results. Initial data indicate that
the cost effectiveness of rapid diagnostic tests is reason-
able in an era of more expensive drugs such as artemi-
sinin combination treatment, and their use could result
in significant savings, especially in areas of low
transmission.18 The national malaria control pro-
grammes of several countries, including Tanzania,
are therefore considering deploying rapid diagnostic
tests in the formal healthcare system as part of the roll
out of artemisinin combination treatment. Although
studies of the technical performance of rapid diagnos-
tic tests (sensitivity, specificity, and stability) are well
advanced, no studies have examined whether their
use actually leads to a change in prescribing practice
compared with current diagnostic methods, which is
fundamental towhether their deploymentwill be effec-
tive and cost effective. We set out to compare rapid
diagnostic tests with routine microscopy in guiding
treatment decisions for febrile patients in outpatient
settings in northeast Tanzania.
METHODS
We did the study in three typical government desig-
nated public hospitals in northeast Tanzania, one each
in areas in which transmission of Plasmodium falciparum
is very low, low-moderate and high (<1, 1-10, and>100
infected bites/person/year). We phased the study to
include the peak malaria transmission season at each
site. In low transmission areasmalaria is seasonal, peak-
ing in January-March; in high transmission areas it is
perennial, peaking in June-August.19 In common with
most hospitals in southern Africa, outpatient care in the
study hospitals is largely provided by clinical officers
with three years’ clinical training.
We invited clinical staff to participate; all agreed and
attended training designed to meet or exceed what
could be provided by a national malaria control pro-
gramme.Training includeddiscussionof rapid diagnos-
tic tests and specifically Paracheck (Orchid Pharmaceu-
ticals), a P falciparum specific (histidine rich protein-2)
test recommended by the national malaria control pro-
gramme in Tanzania that meets World Health Organi-
zation standards for malaria diagnosis and costs
approximately $0.7 (£0.4; €0.5) per test in
Tanzania.2021 The trainers discussed studies showing
94-100% sensitivity and 89-100% specificity for Para-
check and outlined the advantages of visible test results
less prone to false negatives caused by parasite seques-
tration. They reviewed Tanzanian national guidelines
for diagnosis and treatment of malaria to emphasise
that negative malaria tests should lead to alternative
diagnoses being considered.21
Malaria tests were free for the duration of the study,
irrespective of whether patients consented to the study.
Before the trial, we did a baseline observational study
to determine the pattern of routine diagnosis of
malaria. We inspected the prescriptions of all patients
leaving an outpatient consultation and asked them
whether a malaria test had been requested. For those
sent for testing, we recorded the result and subsequent
prescription. A reference slide was taken at the same
time as the routine slide.
The entry criterion for the main trial was a clinician’s
decision to request a malaria test in a patient of any age.
The only patients excluded were those for whom the
clinician specified microscopy or who were admitted as
inpatients for severe disease. Patients with a clinician’s
request for amalaria testwere invited to take part. If they
or their guardians gave informedconsent, a standardised
history was taken, followed by randomisation to rapid
diagnostic test orbloodslidebycomputer generated ran-
dom numbers in blocks of 10; allocations inserted into
opaque envelopeswere opened in front of the patient on
recruitment. All slips had to be accounted for.
Laboratory staff in the clinic did the rapid diagnostic
tests, recorded their result, and gave the test strip to the
patient for the clinician to interpret independently and
record in the review consultation. We used results
recorded by clinicians in the primary analysis of pre-
scribing. Patients randomised to microscopy were
tested according to routine hospital practice, and clin-
icians were given results of the test. We obtained a
reference slide for later double reading in both arms.
Two experienced microscopists blind to allocation
stained reference slideswithGiemsa and counted para-
sites against 200 white blood cells; they examined 100
fields before declaring slides negative. We took a third
reading of discordant results as final.
Clinic staff with the test result (rapid diagnostic test
or hospital slide) reviewed patients in the study and
made clinical decisions that they felt were appropriate.
As patients left, study staff inspected their prescriptions
and recorded them as an objective record of clinicians’
decisions.
Sample size calculation
We designed the study to detect a reduction from an
estimated 45%over-prescription to 25%over-prescrip-
tion in the rapid diagnostic test arm. We needed 128
caseswith negative test results in each arm to detect this
with 95% confidence and 90% power. Estimating that
at high,moderate, and low transmission40%, 70%, and
90% of cases respectively would be slide negative and
allowing for a 25% rate of refusal, we needed a total of
800, 457, and 356 cases at the three transmission
bands. To avoid the possible bias between sites of a
tendency for practice to change over time as health
workers became more familiar and better informed
about the rapid diagnostic test, we decided to recruit
800 cases at each site.
Statistical analysis
We entered data in Microsoft Access and analysed
them with Stata version 9. We finalised the analytical
planbefore analysis. Theprimaryoutcomeof the study
was the proportion of patients in each arm for whom
clinicians requested a malaria test, received a negative
result, and prescribed an antimalarial drug anyway.
We calculated unadjusted odds ratios and then
adjusted them in a logistic regression model with the
pre-defined potential confounding factors of age,
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hospital site, a history of fever, a history of cough (used
as an indicator of a possible non-malarial cause of ill-
ness), and clustering in study sites. We did further ana-
lyses by study site and age group. Secondary outcomes
were the proportion of febrile patients given an anti-
biotic by test outcome and the proportions of patients
for whom antimalarial drugs were correctly pre-
scribed, defined as antimalarial drugs given to patients
with malaria parasites seen and not given to those with
no parasites seen on the research slide. We also used
the double read research slide as a gold standard to
calculate the sensitivity and specificity of the rapid
diagnostic test and hospital slide for each site.
RESULTS
In the one month baseline study, 4081 consultations
took place; 70 (1.7%) of these resulted in presumptive
treatment for malaria, and 2011 (49.3%) resulted in a
request for a malaria slide. For 1813 (90.2%) patients
the slide was reported as negative, and 962 (53.1%) of
these were treated for malaria.
The intervention ran from January to August 2005.
Of 7589 consultations, 63 patients (0.8%) were treated
presumptively for malaria and 2425 (32.0%) were sent
for a malaria test, of whom 2416 (99.6%) consented to
participate and were randomised to rapid diagnostic
test or blood slide (fig 1). Data were incomplete in 19
(0.8%) patients, and results are shown for the remain-
ing 2397 cases. Characteristics of patients in each arm
were similar (table 1).
In all, 523/1030 (50.8%) patients with a negative hos-
pital slide and540/1005 (53.7%)patientswithanegative
rapid diagnostic test were prescribed an antimalarial
drug (odds ratio 1.13, 95% confidence interval 0.95 to
1.34; P=0.18). Rapid diagnostic tests showed no advan-
tage in any of the transmission settings (fig 2); the odds
ratio was 1.16 (0.88 to 1.52) at the low transmission site,
1.00 (0.76 to 1.35) at low-moderate transmission, and
1.17 (0.78 to 1.75) at high transmission. We found a
trend towards an age effect, in that children aged
under 5 were more likely to be treated with an anti-
malarial drug if they tested negative by rapid diagnostic
test than if they tested negative by routine slide (table 2).
The proportion of test negative patients treated with an
antimalarial drug did not vary with the duration of the
trial, whether tested byblood slide (odds ratio 0.99 (0.95
to1.05) perweekof trial duration) orby rapiddiagnostic
test (1.02 (0.97 to 1.07) per week).
Outpatients seen during study (n=7589)
Eligible patients (n=2425; 32%)
Recruited to study (n=2416; 99.6%)
Complete data*
(n=1204; 99%)
Antimalarial
drug
(n=171; 98%)
Antimalarial
drug
(n=523; 51%)
Antimalarial
drug
(n=186; 99%)
Antimalarial
drug
(n=540; 54%)
Positive
(n=174;
14%)
Negative 
(n=1030;
86%)
Positive
(n=188;
16%)
Negative 
(n=1005;
84%)
Presumptive treatment for malaria (n=63; 0.8%)
Complete data*
(n=1193; 99%)
Blood slide
(n=1214; 50%)
Rapid diagnostic test
(n=1202; 50%)
Refused consent (n=9; 0.4%)
Fig 1 | Total clinic attendances and patients recruited to study
bymalaria test result and antimalarial treatment prescribed.
Datamissing fromnine patients randomised to rapid
diagnostic test (eightmissing test result, onemissingage)and
10patients randomised to slide testing (ninemissing slide
result, onemissing age)
Table 1 |Baseline characteristics of patients randomised to blood slide or rapid diagnostic test.
Values are numbers (percentages) unless stated otherwise
Characteristic Slide (n=1204) Rapid test (n=1193)
Median (IQR) age (years) 11.4 (2-30) 7.3 (2-29)
Female 679 (56) 668 (56)
Fever in previous 48 hours 979 (81) 952 (80)
Cough in previous 48 hours 493 (41) 499 (42)
Previous antimalarial drug use in current illness 66 (5.5) 66 (5.5)
Less than eight years’ education* 888 (74) 876 (73)
Less than one hour’s travel to clinic 698 (58) 685 (57)
Median (IQR) reported days ill 3 (2-4) 3 (2-4)
IQR=interquartile range.
*Patient or patient’s mother if patient aged under 15.
Table 2 |Patientswith negative test result treatedwith any antimalarial drug bymalaria test
method and age group, stratified by transmission intensity ofPlasmodium falciparum
Age group
(years)
Slide negative Rapid diagnostic test negative P value*
No No (%) given
antimalarial
No No (%) given
antimalarial
Low transmission
<5 185 116 (63) 172 129 (75) 0.013
5-15 38 17 (45) 35 18 (51) 0.568
>15 193 94 (49) 194 86 (44) 0.388
Total 416 227 (55) 401 233 (58) 0.308
Low-moderate transmission
<5 141 88 (62) 171 110 (64) 0.727
5-15 55 39 (71) 59 44 (75) 0.660
>15 171 103 (60) 156 88 (56) 0.484
Total 367 230 (63) 386 242 (63) 0.995
High transmission
<5 88 20 (23) 78 32 (41) 0.012
5-15 29 14 (48) 25 9 (36) 0.364
>15 130 32 (25) 115 24 (21) 0.486
Total 247 66 (27) 218 65 (30) 0.459
All sites
<5 414 224 (54) 421 271 (64) 0.003
5-15 122 70 (57) 119 71 (60) 0.719
>15 494 229 (46) 465 198 (43) 0.240
Total 1030 523 (51) 1005 540 (54) 0.182
*Statistical significance of associations in each stratum assessed with fully interacted logistic regression model
that included interactions between treatment and indicator variables for each stratum as covariates.
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We used a logistic model to explore associations
between presenting features and prescription of an
antimalarial drug for a patient with a negative test
result. Adults and patients with a history of fever in
the previous 48 hours were more likely to be pre-
scribed an antimalarial drug despite a negative test;
we found no significant association with the type of
test used (table 3). In 203/1063 (19.1%) of cases in
which treatment for malaria was given with a negative
test result, the patient did not report a history of fever.
Antibiotics were prescribed to 51/362 (14.1%)
patients who tested positive for malaria and to 1044/
2035 (51.3%) with a negative test (odds ratio 6.42, 4.72
to 8.75; P<0.001); the difference was especially
marked in children aged under 5 (16.8, 11.3 to 25.1;
P<0.001) (table 4). Prescription of an antibiotic was
not influenced by test method: 525/1030 (51.0%)
slide negative patients and 519/1005 (51.6%) rapid
diagnostic test negative patients were prescribed an
antibiotic (P=0.76), and 308/414 (74.4%) slide negative
and 310/421 (73.6%) rapid diagnostic test negative
children aged under 5 were prescribed an antibiotic
(P=0.80).
Whenwe used double read research slide results as a
gold standard, 269/1420 (18.9%) patients prescribed
an antimalarial drug had P falciparum parasitaemia,
and in the low and low-moderate transmission sites
this proportion fell to 20/1004 (2.0%).Among children
aged under 5, 3/99 (3.0%) tested by rapid diagnostic
test had >2000 asexual P falciparum parasites/µl on
the research slide and did not receive an antimalarial
drug, compared with 4/72 (5.6%) in the hospital slide
group (P=0.41). If we define a correct prescription of an
antimalarial drug as one that is prescribed when para-
sites are present on research slides and not prescribed
when they are not, 616/1193 (51.6%) of patients rando-
mised to the rapid diagnostic test and 606/1204
(50.3%) randomised to a slide test had a correct
prescription of an antimalarial drug (odds ratio 1.05,
0.90 to 1.12; P=0.524).
We comparedhospital slide and rapiddiagnostic test
results with the double read research slide (table 5).
Rapid diagnostic tests generally performed well (both
sensitive and specific) under field conditions. How-
ever, in seven cases the rapid diagnostic test result
was negative according to both the prescribing health
worker and the laboratory assistant but the research
slide was positive; in five of these the parasite density
was >5000 P falciparum parasites/l. In two cases, non-
falciparum species were detected. Hospital laboratory
slide results were less sensitive than rapid diagnostic
tests (71.3% v 95.4%), and 39 reference slide positive
cases were reported as slide negative by the hospital
laboratory; in 13 of these the parasite density was
>5000/l. The agreement between the health worker
and the laboratory assistant in interpreting the rapid
diagnostic test result was high (κ=0.913); 4/996
(0.4%) of rapid diagnostic tests were reported as nega-
tive by the health worker and positive by the labora-
tory assistant, and 22/1014 (2.2%) were reported as
positive by the health worker and negative by the
laboratory assistant.
DISCUSSION
Malaria is the single most common diagnosis in most
hospitals in Africa and consumes a considerable pro-
portion of available resources. During an era of cheap
P=0.308
Negative tests (n=817; 99%) Negative tests (n=753; 92%) Negative tests (n=465; 61%)
P=0.995 P=0.459
Antimalarial
(n=233; 58%)
Antimalarial
(n=227; 55%)
Antimalarial
(n=242; 63%)
Antimalarial
(n=230; 63%)
Antimalarial
(n=65; 30%)
Antimalarial
(n=66; 27%)
RDT negative†
(n=401; 49%)
Slide negative†
(n=416; 51%)
Malaria test* (n=821; 26%) Malaria test* (n=821; 52%) Malaria test* (n=755; 27%)
Very low transmission site
(n=3167)
Low-moderate transmission site
(n=1594)
High transmission site
(n=2828)
RDT negative†
(n=218; 47%)
Slide negative†
(n=247; 53%)
RDT negative†
(n=386; 51%)
Slide negative†
(n=367; 49%)
Fig2 | Clinic attendances,malaria test results,andantimalarial treatmentprescribedateachof the
study sites. *Data are shown for caseswithcomplete data; 3, 3, and13 caseshad incomplete data
in the low, low-moderate, andhigh transmissionsites.†Positive test resultsat low, low-moderate,
and high transmission hospitalswere: rapid diagnostic test 3, 15, and 168; blood slide 1, 53, and
168. All but five patientswith positive tests results were treatedwith an antimalarial drug; reason
for omission of treatment in these five not known
Table 3 |Crude and adjusted oddsof prescribing antimalarial
drug in presence of negative test result formalaria
Crude Adjusted*
Odds ratio
(95% CI)
P value Odds ratio
(95% CI)
P value
Diagnostic test
Blood slide 1 1
Rapid test 1.13 (0.95 to
1.34)
0.182 1.11 (0.97 to
1.26)
0.128
Age group (years)
<5 1 1
5-15 0.97 (0.72 to
1.30)
0.829 1.01 (0.44 to
2.33)
0.978
>15 0.55 (0.46 to
0.67)
<0.001 0.60 (0.38 to
0.94)
0.025
Transmission intensity
Low 1 1
Low-
moderate
1.30 (1.07 to
1.60)
0.010 1.26 (1.20 to
1.31)
<0.001
High 0.30 (0.24 to
0.39)
<0.001 0.28 (0.28 to
0.29)
<0.001
Fever in previous 48 hours
No 1 1
Yes 1.37 (1.11 to
1.69)
0.004 1.56 (1.48 to
1.64)
<0.001
Cough in previous 48 hours
No 1 1
Yes 1.07 (0.90 to
1.28)
0.430 0.86 (0.72 to
1.05)
0.133
*Logistic regression model in which dependent variable was prescription of
antimalarial drug with a negative malaria test result (1) compared with no
antimalarial drug (0); independent variables as specified in table. Standard
errors for adjusted odds account for clustering within study sites.
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and virtually limitless antimalarial drugs, the policy for
treatingmalaria has assumed that it is safer to treat sev-
eral cases of non-malarial febrile illness with an anti-
malarial drug than to miss one true case. Our study
shows that this policy is associated with high levels of
overuse of antimalarial drugs, especially in low-mod-
erate transmission settings where a significant propor-
tion of people in malaria endemic countries of Africa
live.22 Clinicians frequently requested tests, but they
paid limited attention to negative results, irrespective
of intensity of transmission. At the low transmission
site, less than 1% of patients treated with an anti-
malarial drug had malaria parasites in their blood.
Impact of over-diagnosis on cost effectiveness
The potential impact of this level of over-prescription
is considerable. Substantial numbers of cases of poten-
tially fatal febrile illness treatable with affordable anti-
biotics are almost certainly being missed.23 Over-diag-
nosis of malaria on this scale also threatens the
sustainability of deployment of artemisinin combina-
tion treatment. These highly effective drugs are essen-
tial in east Africa, where alternative treatments are fail-
ing, but they are considerably more expensive than
current monotherapy and depend on subsidy from
the Global Fund and others if they are to reach the
poorest groups who are most vulnerable to malaria.24
Sustaining the subsidy for artemisinin combination
treatment, which is essential for malaria in Africa, will
be possible only if this regimen is seen to be cost effec-
tive. These drugs are cost effective if used formalaria in
areas where other drugs have failed, but this depends
on the drug being used for children with true malaria,
as cost effectiveness rapidly falls away at high levels of
misdiagnosis.25Recognising the increasing importance
of accurate diagnosis in an era of more costly artemisi-
nin combination treatment, governments, encouraged
by expert opinion, have been placing substantial
orders for rapid diagnostic tests to guide treatment of
febrile illness. Although rapid diagnostic tests are sig-
nificantly more costly than microscopy in a hospital
setting, they are potentially cost effective, but only if
clinicians using the test act on the result.26
Finding realistic ways to improve the quality of
health care in hospitals in Africa is a priority.27
Although the literature on improving prescribing in
developed countries is extensive, a recent WHO
review identified only 36 trials of strategies to improve
prescribing behaviour in developing countries, of
which six included antimalarial prescribing as a major
outcome.28 Improving diagnosis of febrile illness is
essential but will not be easy. It depends first on
improvements in diagnostic facilities so that clinicians
can rely on diagnostic tests, but then on changes in
longstanding diagnostic behaviour by clinicians. Both
of these are difficult with limited resources, but experi-
ence from Europe in changing antibiotic prescribing
behaviour suggests that encouraging changes in clini-
cians’ behaviour will be the harder of the two.
The challenges for diagnostic laboratories in Africa,
which include defective microscopes, intermittent
power, poor consumables, and limited time to exam-
ine slides, are well known.29 Improving hospital
laboratories to the point where their results are as accu-
rate as a rapid diagnostic test is neither simple nor easy
to sustain.30Rapiddiagnostic tests are theonly new tool
on offer for improving diagnosis ofmalaria bothwithin
the formal sector and where diagnosis is currently
Table 4 |Prescription of any antibiotic for patientswith positive or negativemalaria tests by age group
Age group (years) Positive test Negative test
Antimalarial drug No antimalarial drug
No No (%) given antibiotic No No (%) given
antibiotic
No No (%) given antibiotic
<5 228 33 (14) 495 365 (74) 340 253 (74)
5-15 50 7 (14) 141 49 (35) 100 55 (55)
>15 84 11 (13) 427 143 (33) 532 179 (34)
Total 362 51 (14) 1063 557 (52) 972 487 (50)
Table 5 |Sensitivity, specificity, and predictive values of rapid diagnostic test or routine blood slide as judged against research
slide results
Research slide* Sensitivity (%) (95% CI) Specificity (%) (95% CI) Negative
predictive value
(%)
Positive
predictive value
(%)
Positive Negative
Rapid diagnostic test†
Positive 146 42 95.4 (94.2 to 96.6) 95.9 (94.8 to 97.0) 99.3 77.7
Negative 7‡ 985
Hospital slide
Positive 97 77 71.3 (68.8 to 73.9) 92.8 (91.3 to 94.3) 96.2 55.8
Negative 39§ 991
*Slide results are positive or negative for any Plasmodium falciparum asexual parasites; in addition, two slides were positive for P malariae asexual
parasites.
†Positive by either laboratory technician or prescribing health worker.
‡Parasite densities/l were <1000, 0; 1000-4999, 2; 5000-100 000, 2; >100 000, 3.
§Parasite densities/l were <1000, 15; 1000-4999, 11; 5000-100 000, 8; >100 000, 5.
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syndromic, and they have considerable potential to
improve diagnosis. In this study, rapid diagnostic tests
were more accurate than routine slide testing, and both
patients and clinicians reported liking them. Introdu-
cing them into routine care, free of charge and after deli-
vering targeted training had, however, no impact on the
overuse of antimalarial drugs. Incurring the cost of a test
and thenprescribingantimalarial drugs for patientswith
a negative result represents the worst possible outcome
economically. Deployment of rapid diagnostic tests or
any other diagnostic test to promote the sustainability of
artemisinin combination treatment in Africa is likely to
fail unless ways can be found to bring about a major
change in current prescribing behaviour.
Although rapid diagnostic test and slide results were
equally disappointing in guiding antimalarial treat-
ment, the fact that they both seemed to influence the
decision to prescribe antibiotics is potentially encoura-
ging given the increasing realisation of the importance
of bacterial disease as a cause of infant and childhood
mortality.23 Clinicians with a positive test for malaria
were, however, highly unlikely to prescribe anything
except an antimalarial drug; this is not always appro-
priate, as dual infection occurs in all ages.
Potential limitations of rapid diagnostic tests and this study
Current rapid diagnostic tests have limitations. This
study showed false negative results in patients with
high parasite counts, but we cannot determinewhether
this was because the test was done incorrectly or
because of technical limitations of the test. Possible
technical problems include deletion of HRP-2 genes
in certain parasites,31 “flooding” of the antigen capture
sites, and defects in the device membrane (Anthony
Moody, personal communication, 2006). This sup-
ports the legitimate concern that in areas of very high
malaria transmission, withholding antimalarial drugs
from children under 5 with febrile illness is potentially
hazardous even in the face of negative test results,
although where clinicians intend to treat for malaria
anyway it makes little sense to request a test. In other
epidemiological settings and age groups, the negative
predictive value of tests will be excellent and the risks
of withholding antimalarial drugs from patients with
negative tests will be minimal.
Three reasons exist why this trial might not reflect
reality in the rest of Africa and may wrongly lead to an
impression that deploying rapid diagnostic tests without
major additional interventions will have a limited
impact. Firstly, prescribers might have altered their nor-
mal practice as a result of the study (Hawthorne effect);
however, if anything, this is more likely to have encour-
aged them to follow national policy and take test results
into account. Secondly, the levels of over-diagnosiswere
atypical, but all the available evidence indicates that the
findings of over-diagnosis are wholly typical of hospitals
throughout the continent5-9; these are well run, govern-
ment designated hospitals in a stable area, with staff who
have received training typical forhealthcareproviders in
Africa. Thirdly, the training provided in the trial was not
adequate, but as it was considerably more intensive and
tailored to individual settings thanwouldbepossible in a
national roll out, this seems unlikely to have led to bias
against rapiddiagnostic tests.The fact that rapiddiagnos-
tic tests were a newly introduced technologymight have
affected their use either positively or negatively, but we
found that the tendency to respect negative rapid diag-
nostic tests did not vary with the duration of the trial.
Deploying more expensive antimalarial drugs may
lead to behavioural change, so theoretically the results
of this trial will not reflect what will happen if clinicians
are prescribing artemisinin combination treatment.
The cost of centrally subsidised artemisinin combina-
tion treatment to both clinicians and patients will, how-
ever, be the same as existing drugs, so it seems unlikely
the cost will in itself lead to marked behavioural
change. The study reflects behaviour in a hospital set-
ting, and a substantial proportion of febrile illness
(often the great majority) is treated outside hospital or
not treated at all; a paradox of malaria treatment
throughout Africa is that simultaneously with a high
proportion of patients given antimalarial drugs not
having malaria, a significant proportion (and often
the majority) of those who have malaria are not given
an antimalarial drug.32
Can behaviour be changed?
Rapid diagnostic tests could, if they guided results,
have a major impact on the management of malaria in
Africa.33 This trial shows that providing quick and reli-
able diagnostic tools with basic training may, in itself,
have little impact onoveruse of antimalarial drugs.The
combination of artemisinin combination treatment
and rapid diagnostic tests creates an important oppor-
tunity to both reduce the burden of mortality from
malaria in Africa and improve the treatment of bacter-
ial disease. Understanding the reasons for, and then
changing, the habit of over-prescribing antimalarial
drugs will need to be a priority if the potential benefits
of artemisinin combination treatment are to be rea-
lised; simple technical fixes are unlikely. Our findings
indicate an urgent need to identify and implement
more effective ways to improve the use of antimalarial
and antibiotic treatment in Africa.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Cases of malaria in the community are often missed, but at the same time over-diagnosis of
malaria is widespread in Africa
Rapid diagnostic tests are sensitive and specific for falciparummalaria, and could be cost
effective if their use guided practice
WHAT THIS STUDY ADDS
In areas of low or moderate malaria transmission, malaria is massively over-diagnosed in
hospital outpatients and microscopy results are often ignored
Deploying rapid diagnostic tests for malaria, with standard training, made no difference to
the over-diagnosis of malaria in febrile patients
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